Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William E Carson

Showing results (101-110 of 272) with videos related to

Pageof 28
Sort By:
Cold Spring Harbor Molecular Case Studies|February 17, 2018
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosityLorena P Suarez-Kelly, Keiko Akagi, Julie W Reeser, et al.
Blood|January 5, 2008
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gammaSri Vidya Kondadasula, Julie M Roda, Robin Parihar, et al.
Urologic Oncology|January 13, 2021
Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival timesZachary R McCaw, Anobel Y Odisho, Hemant Chaparala, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
American Journal of Clinical Oncology|May 12, 2010
A pilot study of bevacizumab and interferon-α2b in ocular melanomaKristan D Guenterberg, Valerie P Grignol, Kiran V Relekar, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2019
An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neckAshley Pinette, Elizabeth McMichael, Nicholas B Courtney, et al.
Cancer Immunology, Immunotherapy : CII|January 15, 2008
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assaySri Vidya Kondadasula, Kimberly A Varker, Gregory B Lesinski, et al.
Blood|December 18, 2004
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulationRossana Trotta, Robin Parihar, Jianhua Yu, et al.
NPJ Systems Biology and Applications|March 2, 2019
Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypesKelly E Regan-Fendt, Jielin Xu, Mallory DiVincenzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trialBarbara L Andersen, William B Farrar, Deanna M Golden-Kreutz, et al.
Pageof 28

Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
Cold Spring Harbor Molecular Case Studies|February 17, 2018
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosityLorena P Suarez-Kelly, Keiko Akagi, Julie W Reeser, et al.
Blood|January 5, 2008
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gammaSri Vidya Kondadasula, Julie M Roda, Robin Parihar, et al.
Urologic Oncology|January 13, 2021
Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival timesZachary R McCaw, Anobel Y Odisho, Hemant Chaparala, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
American Journal of Clinical Oncology|May 12, 2010
A pilot study of bevacizumab and interferon-α2b in ocular melanomaKristan D Guenterberg, Valerie P Grignol, Kiran V Relekar, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2019
An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neckAshley Pinette, Elizabeth McMichael, Nicholas B Courtney, et al.
Cancer Immunology, Immunotherapy : CII|January 15, 2008
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assaySri Vidya Kondadasula, Kimberly A Varker, Gregory B Lesinski, et al.
Blood|December 18, 2004
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulationRossana Trotta, Robin Parihar, Jianhua Yu, et al.
NPJ Systems Biology and Applications|March 2, 2019
Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypesKelly E Regan-Fendt, Jielin Xu, Mallory DiVincenzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trialBarbara L Andersen, William B Farrar, Deanna M Golden-Kreutz, et al.
Pageof 28